Studies on the effects of GHRH antagonists on prostate and lung cancers demonstrated their ability to modulate signaling pathways involved in cellular proliferation, survival, metastasis, and apoptosis.[43-45]. The gene discussed is GHRH; the disease is lung carcinoma.